Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the transaction, the chief executive officer directly owned 724,253 shares in the company, valued at $19,627,256.30. This trade represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The shares were sold at an average price of $28.62, for a total transaction of $522,543.96.

Cue Biopharma Stock Performance

NASDAQ:CUE traded up $3.12 during trading hours on Friday, reaching $34.20. The company’s stock had a trading volume of 157,074 shares, compared to its average volume of 195,652. The firm has a market capitalization of $143.64 million, a price-to-earnings ratio of -6.12 and a beta of 2.47. The firm has a 50-day simple moving average of $29.50 and a 200-day simple moving average of $147.28. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Analyst Upgrades and Downgrades

CUE has been the topic of a number of research reports. Wall Street Zen upgraded shares of Cue Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Weiss Ratings upgraded Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of Cue Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. ADAR1 Capital Management LLC bought a new position in Cue Biopharma during the second quarter valued at approximately $1,742,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Cue Biopharma in the second quarter worth about $83,000. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cue Biopharma in the second quarter worth about $722,000. BlackRock Inc. purchased a new position in Cue Biopharma in the 2nd quarter worth about $1,824,000. Finally, Persistent Asset Partners Ltd bought a new stake in Cue Biopharma during the 2nd quarter valued at about $389,000. 35.04% of the stock is currently owned by institutional investors.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.